NGM Bio

About NGM Bio

NGM Bio is a biopharmaceutical company focused on developing life-changing medicines by exploring the frontier of science. Their mission is to translate complex biology into innovative therapeutics with rigor and urgency, aiming to address unmet medical needs and improve human life.

Products & Services

NGM120:A GFRAL/GDF15 antagonist antibody targeting hyperemesis gravidarum (extreme pregnancy sickness) with the EMERALD Phase 2 Clinical Trial underway, and cancer cachexia with plans for a Phase 2 Proof-of-Concept Trial.

Specialties

Drug Development Innovative Therapeutics GDF15 Pathway Research Hyperemesis Gravidarum Treatment Cancer Cachexia Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 122000000 MR: - FA: $122 million FAN: 122000000	D: 2024-07-17 FD: 2024-07-17	1 investors

Series A Latest

2024-07-17

$122.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Diana Peng Bockus

Chief Executive Officer

W

Wendy Yeh

Chief Medical Officer

T

Tianny Szeto

Vice President, Finance

K

Kefei Zhou

Vice President, Biometrics

V

Vladimir Hanes

Vice President, Clinical Development Oncology

W

William Chang

Vice President, Clinical Operations

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

NGM Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised